ライフサイエンスコーパス: potency against

1 pounds, exemplified by 35 and 36, display nM potency against 12-LOX, excellent selectivity over relat

2 er (ST) processes, while having much reduced potencies against 3'-processing (3'-P) reactions.

3 the majority of which exhibit submicromolar potency against 3'-end processing and strand transfer, t

4 ), was synthesized and tested for inhibitory potency against [(3)H]WIN35,428, [3H]citalopram, and [3H

5 d human 5-lipoxygenase (5-LOX) with improved potency against 5-LOX due to its reduction of the iron c

6 the clinically used raltegravir and retained potencies against a panel of IN mutants.

7 from milk and plasma had equal neutralizing potencies against a tier 1 virus (r = 0.65; P < 0.0001),

8 ical development that demonstrates excellent potency against a broad range of dimorphic and filamento

9 ht resulted in an improved antiproliferative potency against a colorectal cancer cell line.

10 ed), with sub- and low micromolar inhibitory potency against a fluorogenic substrate.

11 for compound 5i) and low micromolar cellular potency against a mutant BRAF melanoma cell line, WM266.

12 Complex 1 exhibited unique potency against a panel of cancer cells, including cispl

13 ike the parent molecules, display no loss of potency against a panel of clinically important PI-resis

14 s of this series display good broad spectrum potency against a panel of mutant enzymes.

15 inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutation

16 Compound 12 retains its potency against a panel of Pf isolates with known mechan

17 50), 0.6 muM), which exhibited high in vitro potency against a panel of prostate and breast cancer ce

18 20q also had equivalent potency against a panel of single-drug resistant strains

19 and displayed submicromolar to low nanomolar potency against a panel of TKs, including receptor (plat

20 It exhibited excellent potency against a range of tumor cell lines in vitro and

21 ed systemically to mice and displays greater potency against a spectrum of human cancer cell lines th

22 compound 1C8 as displaying strong anti-HIV-1 potency against a variety of clinical strains in vitro.

23 l peptoid mimics which exhibit high in vitro potency against a variety of Gram-positive and Gram-nega

24 Inhibitor 3d maintains excellent potency against a variety of multi-PI-resistant clinical

25 hermore, this inhibitor maintains impressive potency against a wide spectrum of HIV including a varie

26 8, 10, 12, 14) structures possessed similar potencies against AChE, but the latter structures were m

27 ional constraints, to improve the inhibitory potency against active Src kinase.

28 t tactile allodynia and showed diminished in potency against acute nociception without supraspinal/sp

29 protease inhibitors, MK-5172 had exceptional potency against all HCV genotypes.

30 K inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mutati

31 ibitor (Cinn-GEE) of substantially increased potency against all three enzymes (e.g., K(I) = 5.4 micr

32 eak inhibitors of GlyT1 likewise had similar potency against all three isoforms.

33 ndoxifen (10), displayed elevated inhibitory potency against aromatase and enhanced affinity for estr

34 g of 26 compounds revealed 22 with nanomolar potency against axenically cultured bloodstream trypanos

35 nt to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at

36 antagonists are described that exhibit good potency against B1 and high selectivity over B2.

37 questration was less a factor in determining potency against BCR signaling.

38 e to its being long-acting and having a high potency against blood stage P. falciparum (Pf).

39 MRSA, and VanA and VanB VRE) and impressive potencies against both vancomycin-sensitive and vancomyc

40 The inhibitor exhibits low nanomolar potency against both Aurora A and Aurora B enzymes, exce

41 om triazine to purine, improved the in vitro potency against both cruzain and rhodesain by 350-fold,

42 zinone (BTZ) inhibitors have shown nanomolar potency against both drug-susceptible and multidrug-resi

43 HCV NS5A inhibitor exhibiting submicromolar potency against both G-1a and G-1b replicons.

44 cal models, we required inhibitors with good potency against both human and rodent isoforms.

45 droquinolines (HHQs) that show low nanomolar potency against both pathogenic and transmissible intra-

46 generally resulted in a marginal increase in potency against both pcDHFR and tgDHFR.

47 The latter display high in vitro potency against both sensitive and resistant cancer cell

48 ain variant C184A showed the same inhibitory potency against both TACE forms as wild type TACE Pro.

49 Compound 3a displayed excellent potency against both the PARP-1 and PARP-2 enzymes with

50 inhibitor, Acriflavine, and demonstrate its potency against brain cancer.

51 om films at lower temperature exhibited high potency against breast cancer cells.

52 mune surveillance and superior effector cell potency against cancer cells.

53 ole antifungal with an expanded spectrum and potency against Candida spp., Aspergillus spp., and othe

54 ole antifungal with an expanded spectrum and potency against Candida spp., Aspergillus spp., and othe

55 These compounds exhibit low nanomolar potency against caspase-3 with >120-fold selectivity ove

56 ernative lead candidate 4ab with a nanomolar potency against CDK2 and CDK9 and potent antiproliferati

57 nhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representativ

58 azahypoxanthine skeleton exhibited nanomolar potencies against cell lines representing cancers with d

59 nds are more toxic than baicalein, and their potency against cell growth is compromised by the presen

60 both also enhanced anti-P-gp170 activity and potency against cell growth; however, the presence of P-

61 acid residues that greatly diminish the VCC potency against cells and investigated the interplay bet

62 entification of compounds with low picomolar potencies against certain cancer cell lines.

63 nalogues (e.g., Tb14), some with exceptional potencies against certain cell lines [e.g., Tb32 with IC

64 any of the compounds tested showed excellent potency against chloroquine sensitive and resistant stra

65 Kalihinol B shows similarly high potency against chloroquine-resistant Plasmodium falcipa

66 ility of 1 was associated with (i) decreased potency against cIAP2 and affinity for XIAP BIR3 and (ii

67 amides as HCV protease inhibitors addressing potency against clinically relevant resistant variants.

68 a number of derivatives retained acceptable potency against CPT-1.

69 s (BKIs) that have nearly identical in vitro potency against Cryptosporidium but display divergent PK

70 design additional analogues with inhibitory potency against CYP2C19.

71 Compounds 1-6 showed moderate inhibitory potency against DHFR from Pneumocystis carinii, Toxoplas

72 e-2-carboxamides with low nanomolar in vitro potency against DHODH from P. falciparum, P. vivax, and

73 ate important determinants for Btk inhibitor potency against different signaling pathways and provide

74 5-deaza methotrexate (MTX) on the inhibitory potency against dihydrofolate reductase (DHFR) from diff

75 Given its relatively broad spectrum and potency against diverse Gram-negative pathogens, CHIR-09

76 mely 4a and 4e, have been screened for their potency against DNA topoisomerase II, and it has been ob

77 e newly synthesized compounds exhibited high potency against DNA-PK and potentiated the cytotoxicity

78 necarbonylcinnamoyl groups brings about high potency against drug efflux mediated by P-glycoprotein (

79 3-position of P2 quinoxaline maintain better potency against drug resistant variants, likely due to r

80 esent a novel class of compounds with strong potency against drug sensitive and resistant P. falcipar

81 HSP targeted DOC conjugates exhibited high potency against DU145 cells with an IC(5)(0) of 2.4 nM.

82 Indole 24 is nontoxic and showed increased potency against dynamin I and II in vitro and in cells (

83 behavior of She1 along microtubules and its potency against dynein.

84 effective vaccine into one with significant potency against E7-expressing tumors.

85 ective DNA vaccine into one with significant potency against E7-expressing tumors.

86 A replicon vaccine into one with significant potency against E7-expressing tumors.

87 which demonstrated excellent selectivity and potency against effector human memory T cells (subnanomo

88 mor cell lines and showed superior antitumor potency against EGFR-positive tumor xenografts as compar

89 S138A and E148A in the same peptide retained potency against ENF-escape mutants.

90 l profile is explored in terms of inhibitory potency against enzymes of the PfFAS-II pathway.

91 The potency against Epstein-Barr virus (EBV) was assay-depen

92 Diptericin's submicromolar potency against Escherichia coli strains indicated that,

93 effective vaccine into one with significant potency against established E7-expressing metastatic tum

94 effective vaccine into one with significant potency against established E7-expressing tumors.

95 rs has been developed with greatly increased potency against FabI-containing organisms.

96 quester Y551 was an important determinant of potency against FcepsilonR signaling as Y551 sequesterin

97 Star 27 maintains potency against FLT3 in proliferation assays of FLT3-tra

98 -folate and demonstrated its selectivity and potency against folate receptor 1 (FOLR1)-expressing ova

99 Furthermore, CCG205432 retains similar potency against fully infectious virus in cultured human

100 set of furin inhibitors with nanomolar range potency against furin when assayed in a biochemical clea

101 discovered to date that exhibits equivalent potency against FXIa.

102 idity of BILN 2061, while conferring greater potency against genotype 1, rendered it more sensitive t

103 in inhibitor 41H (GSK2236805) supported high potency against genotypes 1a and 1b as well as in genoty

104 ed to 4-methyl hexanoic acid, having similar potency against Gram negative and Gram positive pathogen

105 ative chemistry efforts improved biochemical potency against gram-negative isozymes 300-fold and affo

106 zation of the LPS barrier, thereby improving potency against Gram-negative pathogens.

107 Its potency against Gram-negative strains was comparable (on

108 Synthetic araiosamines were shown to exhibit potency against Gram-positive and -negative bacteria des

109 idue antimicrobial peptide with bactericidal potency against Gram-positive bacteria such as Listeria.

110 ibitors and explained their relative lack of potency against gram-positive GlmU isozymes.

111 all current PIs exhibit significantly lower potency against GT-3.

112 The combination of high potency against HCMV deltaAla protease and high human pl

113 Compound 5 g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of approximately

114 containing lead compounds were optimized for potency against Helicobacter pylori DHODase.

115 omolar concentrations and displays excellent potency against hepatitis B virus (HBV) and varicella-zo

116 type-specific immune responses with limited potency against heterologous viral strains and genotypes

117 potency but dramatically lowered inhibition potency against hGV and hGX sPLA(2)s.

118 The data show a modest trend for lower potency against higher expressing lines.

119 pounds show single-digit nanomolar antiviral potencies against HIV vectors that carry wild-type (WT)

120 T-derived 1,2,3-triazoles with submicromolar potencies against HIV-1.

121 Several ProTide compounds showed substantial potency against HIV-1 at low micromolar range while the

122 d to synthesize compounds with: (1) improved potency against HIV-1 integrase, (2) improved anti-HIV e

123 to the discovery of molecules with improved potency against HIV-1 RT.

124 several bnMAbs remarkable for their in vitro potency against HIV.

125 kappaM-RIIIJ is a determinant of its higher potency against hKv1.2.

126 Although both compounds display similar potencies against human topoisomerase IIalpha and IIbeta

127 The most active agent, 2j, showed high potency against human cancer cells with IC50s ranging fr

128 Compound 2 had inhibitory potency against human DHFR similar to N-[4-[2-(amino-3,4

129 abrogating the previously reported antiviral potency against human immunodeficiency virus (HIV-1).

130 ective DNA vaccine into one with significant potency against human papillomavirus type 16 E7-expressi

131 3b would preserve transport selectivity and potency against human tumor cells, 3b regioisomers with

132 These compounds show modest to high potency against human umbilical vein endothelial cell pr

133 side aryl ring, while having good inhibitory potencies against IN in extracellular assays, are not an

134 zed pyrrolyl derivatives that exhibited good potency against IN and a moderate inhibition of the RNas

135 5-substituted analogs exhibit low micromolar potency against in vitro cultures of drug-resistant and

136 r in the thiazole ring appears important for potency against IN, as its replacement with an oxygen or

137 ning only a salicylic acid showed inhibitory potency against IN, none of the compounds containing onl

138 up (e.g. 5-13) showed significant inhibitory potency against IN, while the presence of either salicyl

139 available JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).

140 iscovered which exhibit in vitro and in vivo potency against key respiratory pathogens.

141 erating compound E67-2) has no effect on the potency against KIAA1718 but, unexpectedly, lost inhibit

142 kemic cell lines expressing these mutations (potency against KIT D816Y >> D816F > D816V).

143 ted extraordinary neutralization breadth and potency against large panels of cross-clade pseudoviruse

144 (20), resulting in an 18-fold improvement in potency against lck and a 50-fold increase in potency in

145 , a first generation lead with low nanomolar potency against life MeV and attractive physical propert

146 igands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostat

147 These compounds display enhanced potency against LpxC in enzymatic assays and superior an

148 ion with front-line antibiotics enhanced the potency against M. tuberculosis by more than 100-fold, t

149 d TAC-derived analogues have shown increased potency against M. tuberculosis.

150 Most of the compounds showed micromolar potency against malaria, with seven of them having IC50

151 taining potent TACE inhibition, but reducing potency against matrix metalloproteases (MMPs) thus incr

152 ear whether these antibodies exhibit similar potency against mature dendritic cell (mDC)-mediated HIV

153 g a (14)C-lactate transport assay, and their potency against MCT1-expressing human tumor cells was es

154 Overall, TMC114's potency against MDR viruses is likely a combination of i

155 time in this series, 16a' provided nanomolar potency against MMP-1, -7, and -9 (IC(50)'s = 110, 140,

156 These reverse amides also exhibited less potency against monoamine oxidase (MAO) enzymes and thus

157 ise contribute to neutralization breadth and potency against most primary virus strains.

158 drophobic surface, providing a basis for its potency against MRSA known to deploy positively charged

159 uinolone-class compounds that have increased potency against Mtb and the ability to overcome resistan

160 This inhibitor maintained near full potency against multi-PI-resistant clinical HIV-1 varian

161 of Aurora kinase inhibitor 14a revealed that potency against multidrug-resistant cell lines was compr

162 f these taxoids exhibited exceptionally high potency against multidrug-resistant cell lines, and seve

163 C220, KW-2449, sorafenib, and sunitinib) for potency against mutant and wild-type FLT3, as well as fo

164 These changes allow it to retain potency against mutations that otherwise would render th

165 2-carboxamide analog (1), had low micromolar potency against Mycobacterium tuberculosis (Mtb), high m

166 one with improved in vitro and intracellular potency against Mycobacterium tuberculosis, including mu

167 These compounds showed high in vitro potency against Mycobacterium tuberculosis, the etiologi

168 f protoxin II-NHCH3, a molecule with greater potency against Nav1.7 channels (IC50=42 pM) than the or

169 ctive metabolite of 1, has retained in vitro potency against newly emerging antifolate-resistant mala

170 ynthesis of LCL204, with enhanced inhibitory potency against NMT1.

171 An unsubstituted amide bond is necessary for potency against nNOS.

172 Compound 11 demonstrated the greatest potency against NOS-mediated citrulline formation for ea

173 PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the

174 l of 30 kinases, and found to have nanomolar potency against only JAK3.

175 These compounds were assessed for their potency against P-gp and another transporter (MRP1), for

176 Th17 clones and rhIL-26 lacked antimicrobial potency against P. acnes.

177 l spectrum of activity, exhibiting excellent potency against P. aeruginosa (MIC(90), 2 microg/ml) and

178 bination of poor plasma exposure and reduced potency against P. berghei DHODH.

179 was to identify indolequinones with improved potency against pancreatic cancer and to define their me

180 Several new PIs exhibit nanomolar antiviral potencies against patient-derived wild-type viruses from

181 Its potency against Pc DHFR was 140-fold greater than that o

182 ersely, N-terminal acetylation increased the potency against PC2 nearly 3-fold, whereas C-terminal am

183 of 8 resulted in a 9- and 8-fold increase in potency against pcDHFR and tgDHFR, respectively.

184 ty in rats, dogs, and monkeys while the high potency against PDE5 and desirable selectivity versus ot

185 Medicinal chemistry optimization of the potency against Pf and ADME properties resulted in the i

186 ounds, 7 and 8 showed the highest inhibitory potency against Pf enoyl-ACP-reductase (PfFabI), followe

187 properties and PK parameters, low nanomolar potency against PI3Kalpha and mTOR, and excellent inhibi

188 the most selective inhibitor with excellent potency against pjDHFR.

189 We sought to identify compounds with higher potency against Plasmodium DHODH while showing greater s

190 ances over azithromycin in vitro in terms of potency against Plasmodium falciparum (over 100-fold) an

191 s of arterolane (OZ277) had little effect on potency against Plasmodium falciparum in vitro.

192 , transition state analogs that exhibit high potency against PNP in the malaria parasite Plasmodium f

193 alogues with improved antibacterial in vitro potency against polymyxin resistant recent clinical isol

194 , known as Hoechst nuclear stains, with high potency against poxvirus infection.

195 d that possesses increased cytotoxicological potency against prokaryotic cells compared to eukaryotic

196 The design of inhibitors with enhanced potency against proteolytic enzymes has many application

197 ) = 58 muM), which has reasonable inhibition potency against Pseudomonas aeruginosa TMK (PaTMK), was

198 eversible, slow-binding inhibitors of modest potency against PTP1B, SHP-1, and a dual-specificity pho

199 resveratrol has a broad range of inhibitory potencies against purified PKC that depend on the nature

200 e rounds of optimization to improve compound potency against purified enzyme and intracellular Plasmo

201 L-chicoric acid (3) which are important for potency against purified HIV-1 integrase and for reporte

202 h the parent tetracycline exhibited marginal potency against purified IN, all substituted tetracyclin

203 thdrawing groups did not enhance nor abolish potency against purified IN.

204 meric D-chicoric acid (4) retains inhibitory potency against purified integrase equal to its L-counte

205 mpound against the parasite enzymes with its potency against rat liver DHFR.

206 e region (analogue 3) doubled the inhibitory potency against recombinant human (rh) DHFR (IC(50) = 0.

207 plasmin in the subnanomolar range, and their potency against related trypsin-like serine proteases in

208 ately improved ( approximately 2- to 4-fold) potencies against replicating Mycobacterium tuberculosis

209 dition to the antiviral inhibitors with high potency against resistant strains of HIV.

210 indicative of once-daily dosing and superior potency against resistant viral strains.

211 ci (VRE), and fluoroquinolones with improved potency against respiratory pathogens and multidrug-resi

212 y reported; however, the greater decrease in potency against rlDHFR compared to pcDHFR and tgDHFR res

213 1 RT in the micromolar range while retaining potency against RT variants carrying one of three major

214 re the preferred pattern of substitution for potency against RT.

215 nds studied, 46a,b showed not only very good potency against RXRalpha (K(i) = 6 nM) but was also foun

216 the MPER antigens but also in neutralization potency against sensitive HIV-1.

217 Compound 40 exhibits high potency against several BRAF(V600E)-dependent cell lines

218 d 3 demonstrated increased growth inhibitory potency against several human tumor cell lines in cultur

219 ilino)-6,7-dimethoxyquinazoline, had a 15 nM potency against Src TK and was selective over receptor t

220 in-based inhibitors with 9-18-fold increased potency against Staphylococcus aureus (Sa) and Bacillus

221 ed by its ability to impart greater relative potency against stromelysin when larger hydrophobic grou

222 lead compound, 17b, that exhibited nanomolar potency against T. brucei with excellent selectivity for

223 ity in cell-free assays, and a submicromolar potency against T315I Bcr-Abl expressing cells.

224 diaminopyrimidine-based inhibitors with good potency against T790M-containing mutants of EGFR, high s

225 Additionally, compound 32 shows potency against TAF1, a bromodomain-containing transcrip

226 effective compound, 22 (MN-64), showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and

227 cidal activity was developed on the basis of potency against TbcatB and various calculated physical p

228 et of inhibitors designed to possess varying potencies against the deformylase enzyme revealed a line

229 t the tumor cells, but some of them had high potencies against the L1210 cells and were more potent a

230 yrosine kinase inhibitors with low nanomolar potencies against the members of the VEGFR and PDGFR kin

231 have been synthesized and tested for binding potencies against the three cloned human NT receptors (h

232 These antibodies exhibited high potency against the 2009 virus in vitro, and one exerted

233 ounds from this series demonstrated in vitro potency against the 3D7 and Dd2 strains of P. falciparum

234 high bioavailability and its nanomolar-range potency against the antiangiogenic receptor tyrosine kin

235 lular calcium mobilization and a much higher potency against the chemerin(149-157) nonapeptide-induce

236 ts have shown a 40-fold and 200-fold loss in potency against the CRFR1 H199V and M276I mutant recepto

237 ized compounds, 22 showed excellent in vitro potency against the cultured parasites (W2 IC(50) = 13 n

238 tifolate, trimethoprim, because of a lack of potency against the dihydrofolate reductase enzyme.

239 refore, the retained and improved inhibitory potency against the drug-resistant variants A156T, D168V

240 The series showed broad potency against the drug-resistant W2 strain of P. falci

241 taxoids exhibited virtually no difference in potency against the drug-sensitive and drug-resistant ce

242 because (i) a 65828 analogue with much lower potency against the enzymatic activity of ANG failed to

243 ring resulted in inhibitors of equal or less potency against the enzyme and decreased efficacy in a c

244 Until recently, despite achieving high potency against the enzyme, these efforts have been thwa

245 , have demonstrated profound selectivity and potency against the FLT3 target, and are currently being

246 otency (IC(50) = 0.42 microM) as well as the potency against the growth inhibition of tumor cells in

247 Compound 4t has excellent potency against the HCV 1b replicon, with an EC50 = 2 nM

248 in 5A (NS5A), such as daclatasvir, have high potency against the hepatitis C virus (HCV).

249 ic nitrogen while still maintained excellent potency against the hGnRH receptor.

250 these compounds show low to high inhibitory potency against the human CYP17 enzyme.

251 Remarkable potency against the IN in the absence of divalent metals

252 ike growth factor receptor kinase with equal potency against the insulin receptor is described.

253 on of inhibitors with significantly improved potency against the key resistant variants and with incr

254 he optimized compounds display low nanomolar potency against the mast cell target and several hundred

255 re were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replico

256 pectrum antimicrobial activity, and enhanced potency against the opportunistic human pathogen Acineto

257 revealed that an inhibitor with insufficient potency against the p110beta isoform was less effective

258 ies of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from th

259 Compound 22b displayed excellent potency against the PARP-1 enzyme with a K(i) of 1 nM an

260 yclic inhibitors displayed 20-50-fold higher potency against the PDF active site (K(I) as low as 70 p

261 microM), but a more substantial increase in potency against the rat liver DHFR led to a reduction in

262 be nzothiophen-1-yl]acetamide) combined high potency against the target enzyme (DNA-PK IC = 8 nM) wit

263 These exhibit enhanced potency against the target in binding and functional ass

264 on of the series scaffold to further enhance potency against the target while also improving pharmaco

265 ciating rate, thus increasing its anti-HIV-1 potency against the temporarily exposed target in NHR an

266 icinal chemistry campaign to achieve greater potency against the trypanosome.

267 l group of Cys181 that helps the drug retain potency against the Tyr181Cys mutation.

268 This level of potency against the unactivated form of VLA-4 was shown

269 ionale to the drastic decrease in inhibitory potency against the V27A variant.

270 This loss of potency against the yeast enzyme correlated with a compl

271 ed against the full-length human enzyme, the potency against the yeast enzyme has decreased significa

272 rmation to that of IGF-1R/IR, explaining the potency against these two structurally distinct kinase f

273 less active than predicted from its in vitro potency against this pathogen.

274 ynergistic effect and significantly enhanced potency against three esophageal adenocarcinoma cell lin

275 ycin (mTOR) that also showed high inhibitory potency against Trypanosoma brucei cultures.

276 NCI 60 human tumor cell line and significant potency against tubulin assembly (IC50 0.812 muM).

277 cells), demonstrating 3- to 10-fold greater potency against tumor cell lines when compared with norm

278 ession correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1

279 nylacetamido moiety in order to increase the potency against (V600E)BRAF compared to CRAF.

280 /= 0.008 to 0.12 mug/mL), including enhanced potency against vancomycin-resistant enterococci.

281 The V-V series displayed the greatest potency against vancomycin-susceptible organisms and van

282 ainst HIV strains with wild-type RT but lose potency against variants with single Y181C and double K1

283 le round replication assay and have improved potency against vectors harboring the major forms of dru

284 The molecule was evaluated both in vitro for potency against VEGF and in ocular VEGF-driven efficacy

285 scovery of second generation inhibitors with potency against viral strains bearing drug resistant IN

286 ough these prototype inhibitors have similar potencies against wild-type c-Met (K(i) = 6-7 nM), signi

287 Both compounds displayed low nanomolar potency against wild type HIV in the presence of human s

288 the higher affinity T20 variant had similar potency against wild type HIV-1.

289 Such adaptations appear to be critical for potency against wild-type and a wide range of drug-resis

290 cussed, focusing on optimization of cellular potency against wild-type and drug resistant parasites a

291 on of 8e (MK-4965), which has high levels of potency against wild-type and key mutant viruses, excell

292 n a high throughput screening, with moderate potency against wild-type GCase.

293 critical pharmacophore for enhanced in vitro potency against wild-type hepatitis C replicons and know

294 small-molecule SRC/ABL inhibitors also have potency against WT KIT kinase.

295 31N with potencies greater than amantadine's potency against WT M2.

296 This compound possessed excellent potency against WT RT and key clinically observed RT mut

297 w analogue compound 2 that maintains greater potency against Y181C and K103N/Y181C variants and bette

298 ipyridodiazepinone skeleton confers enhanced potency against Y181C RT.

299 , we now demonstrate that KP1019 retains its potency against yeast carrying the hypermorphic alleles

300 th ZIKV(C) and ZIKV(M) in hNPCs, with higher potency against ZIKV(C)-induced apoptosis.